Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival.
Animals
Biomarkers
Carcinoma, Hepatocellular
/ etiology
Cell Line, Tumor
Clinical Trials, Phase II as Topic
Cytokines
Disease Models, Animal
Flavonoids
/ pharmacology
Hepatitis B
/ complications
Humans
Immunomodulation
/ drug effects
Kaplan-Meier Estimate
Liver Neoplasms
/ etiology
Lymphocyte Activation
Mice
Multicenter Studies as Topic
Myeloid-Derived Suppressor Cells
/ drug effects
Neoplasm Staging
Prognosis
Treatment Outcome
HBV-related advanced HCC
dynamic biomarker
icaritin anticancer immunomodulation
survival
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
20
04
2020
revised:
27
07
2020
accepted:
25
08
2020
pubmed:
6
9
2020
medline:
22
12
2020
entrez:
5
9
2020
Statut:
ppublish
Résumé
Advanced hepatitis B virus (HBV)-related hepatocellular carcinoma HCC with poor prognosis is often associated with chronic inflammation, immune tolerance, and marked heterogeneity. The interleukin-6 (IL-6)/JAK/STAT3 signal pathways play multiple regulatory roles in modulating inflammation and immunity in cancers. Polarization of myeloid-derived suppressor cells (MDSCs) is involved in HBV-related immunosuppression and CD8
Identifiants
pubmed: 32889778
doi: 10.1111/cas.14641
pmc: PMC7648021
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Flavonoids
0
icaritin
UFE666UELY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4218-4231Subventions
Organisme : China Postdoctoral Science Foundation
ID : 2018M643316
Organisme : Beijing Shenogen Biomedical Ltd.
Organisme : National Science and Technology Major Project
ID : 2012ZX09101215
Organisme : National Natural Science Foundation of China
ID : 81903093
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Clin Cancer Res. 2014 Apr 15;20(8):2072-9
pubmed: 24589894
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Nat Rev Drug Discov. 2015 Sep;14(9):603-22
pubmed: 26228631
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86
pubmed: 27141885
Cancer Sci. 2020 Nov;111(11):4218-4231
pubmed: 32889778
PLoS One. 2014 Jul 21;9(7):e103008
pubmed: 25047809
Gut. 2019 May;68(5):916-927
pubmed: 29970455
NPJ Precis Oncol. 2018 Feb 23;2(1):6
pubmed: 29872724
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
PLoS One. 2011;6(8):e23720
pubmed: 21887305
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Sci Rep. 2016 Mar 11;6:22995
pubmed: 26965318
Cancers (Basel). 2019 Aug 30;11(9):
pubmed: 31480382
Cancer Sci. 2017 Oct;108(10):1947-1952
pubmed: 28749573
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
J Immunol. 2015 Nov 15;195(10):4873-83
pubmed: 26416274
J Clin Oncol. 2017 Feb 20;35(6):622-628
pubmed: 28045619
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Clin Cancer Res. 2017 Sep 1;23(17):4970-4979
pubmed: 28864725
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Oncotarget. 2015 Oct 13;6(31):31927-43
pubmed: 26376676
Gastroenterology. 2019 May;156(6):1731-1741
pubmed: 30738047
Oncotarget. 2016 Dec 13;7(50):83755-83766
pubmed: 27835879
Nat Rev Drug Discov. 2019 Nov;18(11):827-844
pubmed: 31455905
Int Immunopharmacol. 2011 Jul;11(7):890-8
pubmed: 21244860
N Engl J Med. 2013 Jan 10;368(2):161-70
pubmed: 23301733
Liver Cancer. 2020 Apr;9(2):167-181
pubmed: 32399431
Dig Dis. 2014;32(6):705-10
pubmed: 25376287
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
Viruses. 2017 Apr 29;9(5):
pubmed: 28468285
Nat Rev Immunol. 2007 Jan;7(1):41-51
pubmed: 17186030
Lancet Oncol. 2013 May;14(6):e218-28
pubmed: 23639322
Eur J Immunol. 2019 Dec;49(12):2235-2244
pubmed: 31465113
Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):74-75
pubmed: 31712772
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Mediators Inflamm. 2018 Aug 27;2018:7235639
pubmed: 30224899
BMC Cancer. 2019 Mar 28;19(1):279
pubmed: 30922248
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604
pubmed: 31439937
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58
pubmed: 26598942
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Nat Rev Clin Oncol. 2019 Sep;16(9):563-580
pubmed: 31092901
Cancers (Basel). 2019 Nov 01;11(11):
pubmed: 31683891
Biomed Pharmacother. 2018 Apr;100:358-366
pubmed: 29453045
Cell. 2010 Jan 22;140(2):197-208
pubmed: 20141834
Nat Rev Clin Oncol. 2015 Aug;12(8):436
pubmed: 26099984
J Immunol. 2000 Jul 15;165(2):956-61
pubmed: 10878371
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
Clin Chem Lab Med. 2016 Dec 1;54(12):1963-1969
pubmed: 27010778
Mol Cancer. 2011 Dec 15;10:150
pubmed: 22171994
Front Immunol. 2019 Aug 27;10:2048
pubmed: 31507621
J Hepatol. 2018 Jun;68(6):1181-1190
pubmed: 29427729
Phytomedicine. 2018 May 15;44:74-84
pubmed: 29895495
Br J Cancer. 2016 Mar 15;114(6):642-9
pubmed: 26908330
Clin Cancer Res. 2018 Aug 15;24(16):3857-3866
pubmed: 29716923
Front Plant Sci. 2015 Aug 25;6:655
pubmed: 26379683
Gastroenterology. 2017 May;152(6):1297-1309
pubmed: 28219691
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Clin Microbiol Rev. 2012 Jan;25(1):2-41
pubmed: 22232370
Gut. 2018 May;67(5):945-952
pubmed: 29055908
Hepat Mon. 2016 Mar 26;16(4):e35810
pubmed: 27257429
Eur J Cancer. 2012 Jul;48(10):1452-65
pubmed: 22240282
Nat Rev Gastroenterol Hepatol. 2016 Nov;13(11):643-653
pubmed: 27625189
J Clin Invest. 2018 Aug 1;128(8):3425-3438
pubmed: 29771686